Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
A legfontosabb adatok
- Ki végzi
- Assistance Publique - Hôpitaux de Paris
- Hol
- Franciaország9 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 3. fázis
- Résztvevők
- 80 fő, tervezett
- Kezdés
- 2024. aug. 14.
- Várható befejezés
- 2027. nov.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Letermovir
- Valganciclovir
- Letermovir placebo
- A regiszteradat frissítve
- 2026. január 2.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with a kidney transplant who have a CMV (cytomegalovirus) infection that needs valganciclovir treatment. It compares letermovir plus valganciclovir with placebo plus valganciclovir.
- Életkor
- 18 years and older
- Nem
- All sexes
- A betegség stádiuma
- Documented CMV infection or disease. Weight 30 kg (66 lb) or more. Life expectancy of 8 weeks or more. The doctor judges that you can take oral valganciclovir.
- Korábbi kezelés
- You cannot join if you have taken anti-CMV drugs (ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir or maribavir) for this infection for longer than 72 hours. People who got the infection while on preventive ganciclovir, valganciclovir or letermovir can join. No anti-CMV vaccine ever.
- Biomarker vagy leletérték
- CMV DNA ≥ 3000 IU/mL in blood in 2 tests at least 1 day apart, or CMV DNA ≥ 30000 IU/mL in 1 test, measured by qPCR.
A részvétel fő kizáró okai
- CMV known to be resistant to valganciclovir and/or letermovir
- eGFR < 15 mL/min/1.73m² (very low kidney function) or severe liver disease (Child-Pugh Class C)
- Needing a breathing machine or drugs to support blood pressure
- Pregnant or breastfeeding
- HIV infection with plasma HIV RNA ≥ 50 copies/mL in the last 3 months
Ez a vizsgálat csak szervátültetésen átesett résztvevőket keres. A regiszter mondata, amelyen ez alapul: 3. Kidney transplant recipient
A regiszter feltételei, szó szerint
Mind a 28 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 18 years
- Weight ≥ 30 kg
- Kidney transplant recipient
- Have a documented CMV infection or disease, with (i) a screening value of CMV DNA ≥ 3000 IU/mL in whole blood or plasma in 2 consecutive assessments separated by ≥ 1 day, as determined by local laboratory quantitative polymerase chain reaction (qPCR). Both samples should be taken within 14 days prior to randomization with the second sample obtained within 5 days prior to randomization OR (ii) a screening value of CMV DNA ≥ 30000 IU/mL in whole blood or plasma, as determined by local laboratory quantitative polymerase chain reaction (qPCR), in 1 sample obtained within 5 days prior to randomization
- Eligible for treatment with oral valganciclovir, per investigator's judgment
- For patients of childbearing age (following menarche): negative bHCG and effective method of contraception (sexual abstinence, hormonal contraception containing ethinylestradiol and levonorgestrel, intrauterine device or hormone-releasing system, cap, diaphragm or sponge with spermicide, condom) until 30 days after the end of relevant systemic exposure (week 13); For male an effective method of contraception (sexual abstinence, condom) until 90 days after the end of relevant systemic exposure (week 13)
- Have life expectancy of ≥ 8 weeks
- French speaking
- Affiliated to social security regime or an equivalent system
- Informed consent and signed
Ki nem vehet részt
- Be on treatment with anti-CMV agents (ganciclovir, valganciclovir, foscarnet, cidofovir, letermovir or maribavir) for the current CMV infection for longer than 72 hours. However, patients experiencing CMV infection while receiving ganciclovir or valganciclovir prophylaxis (i.e. at prophylactic dosages) or letermovir prophylaxis can be included
- Have a known human immunodeficiency virus (HIV) infection with plasma HIV RNA ≥ 50 copies/mL within the 3 months before inclusion
- Have received anti-CMV vaccine at any time
- Be receiving leflunomide or artesunate when study treatment is initiated
- Be receiving strong inhibitors or inducers of hepatic CYP enzymes including rifampicin, phenytoin, clarithromycin, ritonavir, or cobicistat or St. John's wort (Hypericum perforatum) when study treatment is initiated
- Be receiving efavirenz, etravirine, nevirapine, lopinavir, pimozine, ergot alkaloids, dabigatran, atorvastatine (at a daily dose > 20mg, and / or if co-administered with cyclosporin A), pravastatin ( if co-administered with cyclosporin A), simvastatine, rosuvastatine, pitavastatine or imipenem-cilastatine when study treatment is initiated
- Have a current CMV infection that is considered refractory or resistant due to inadequate adherence to antiviral treatment, to the best knowledge of the investigator
- Have a CMV infection that is known to be genotypically resistant to valganciclovir and/or letermovir on documented evidence
- Have a severe chronic liver disease (Child-Pugh Class C)
- Have known hypersensitivity to letermovir or to an excipient for a study treatment
- Have any clinically significant medical or surgical condition that in the investigator's opinion could interfere with the interpretation of study results, contraindicate the administration of the assigned study treatment, or compromise the safety or well-being of the subject
- Have an eGFR < 15 mL/min/1.73m² (using the CKD-EPI Creatinine Equation (2009))
- Have serum aspartate aminotransferase (AST) ≥ 5 times higher than the upper limit of normal (ULN), or serum alanine aminotransferase (ALT) ≥ 5 times the ULN, or total bilirubin ≥ 3 times the ULN (except for documented Gilbert's syndrome). Note: Subjects with biopsy confirmed CMV hepatitis will not be excluded from study participation despite AST or ALT ≥ 5 times ULN
- Have known hereditary intolerance to galactose, with lactose Lapp deficiency, glucose or galactose malabsorption syndrome
- Have an absolute neutrophil count less than 500 cells/µl, or platelet count less than 25,000/µl, or haemoglobin less than 8 g/dl
- Require mechanical ventilation or vasopressors for hemodynamic support
- Be pregnant or breastfeeding
- Participation to another clinical trial on medicinal products for human use
Ez a vizsgálat jelenleg itt érhető el: Franciaország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to evaluate the efficacy and the tolerance of letermovir as part of dual antiviral therapy (in association with valganciclovir) in renal transplant recipients with CMV DNAemia, requiring valganciclovir treatment per investigator's judgment.
A vizsgálat 2 csoportja
- Letermovir+ValganciclovirA vizsgált kezelés
Daily administration of Letermovir plus Valganciclovir
Kezelés: Letermovir és Valganciclovir
- Letermovir Placebo+ValganciclovirMár használt kezelés, összehasonlításként
Daily administration of Letermovir placebo plus Valganciclovir
Kezelés: Valganciclovir és Letermovir placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Letermovir/Valganciclovir Combination Versus Valganciclovir Monotherapy for Treatment of Cytomegalovirus (CMV) Infections in Kidney Transplant Recipients
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. január 2.